Alectos Supports NSERC Funding for Prof. A.J. Bennet at SFU
Feb 11, 2016 – Alectos today announced its support for [...]
O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson’s disease
Several aggregation-prone proteins associated with neurodegenerative diseases can be modified [...]
Alectos Engages As Industry Partner in the Canadian Glycomics Network (GlycoNet)
Feb 17, 2015 – Alectos today announced its support as [...]
Structures of lactate dehydrogenase A (LDHA) in apo, ternary and inhibitor-bound forms
Lactate dehydrogenase (LDH) is an essential metabolic enzyme that catalyzes [...]
Fluorescence-quenched substrates for live cell imaging of human glucocerebrosidase activity
Deficiency of the lysosomal glycoside hydrolase glucocerebrosidase (GCase) leads to [...]
Alectos Therapeutics Announces Achievement of Phase I Clinical Milestone in Merck Alzheimer’s Collaboration
Vancouver, British Columbia (December 12, 2014) – Alectos Therapeutics Inc. [...]
Alectos Announces Preclinical Results in TAPP Mouse Model of Alzheimer’s Disease
Oct 26, 2014 – Alectos today announced publication of preclinical [...]
Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice
BACKGROUND: Amyloid plaques and neurofibrillary tangles (NFTs) are the defining [...]
The emerging link between O-GlcNAc and Alzheimer disease
Regional glucose hypometabolism is a defining feature of Alzheimer disease [...]
Alectos Supports NSERC Funding for Prof. M.J. Boulanger at UVic
Oct 6, 2014 – Alectos today announced its support for [...]